WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation...
Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three months ended March 31, 2026 ...
The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness Day This social media–driven initiative invites people to wear a hat, share a photo, and help raise awareness of AK and the importance of comprehensive sun protectio...
WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial result...
Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, t...
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial resu...
• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further clinical development • Acne vulgaris represents a promising poten...
WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board (th...
Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansion Data to complement previously announced positive Phase 3 efficacy results on extremities, neck and trunk Supplemental NDA submission for extremities, neck and trunk indication expected in Q3 202...
Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026 If approved, Ameluz ® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma (sBCC) in the US BCC is the most common skin cancer in the US with 3.6...
Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz ® vs. vehicle gel (p<0.0003) Actinic keratosis (AK) is the most common skin condition diagnosed by US dermatologists 1 If left untreated, AK may progress to squamous cell carcino...
Fourth quarter results represent highest quarterly revenue in Company’s history Q4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz ® Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GL...
Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026 Data generated will support key regulatory milestones for Ameluz PDT in both indications AK and acne are the two most commonly diagnosed skin disorders in the US 1 WOBURN, Mass., Jan....
• Ameluz ® and RhodoLED ® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc. • Assignment to Biofrontera Inc. of 11 granted US patents, 10 pending US patent applications and various t...
Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz ® over treatment area of 240 cm 2 Completion of this study marks a key milestone towards a planned summer 2026 FDA submission for FDA approval for the use of Ameluz...
sNDA for treatment of sBCC with Ameluz ® -PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025 First Phase 3 PDT study in patients with sBCC in the United States submitted to FDA Primary and key secondary endpoints met with high statistical significance (...